The RESONATE-2 trial reveals ibrutinib's long-term efficacy and safety in treating CLL/SLL, especially for high-risk patients ...

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk ...

Just a month after AbbVie and Genmab got FDA approval for Epkinly in one form of non-Hodgkin’s lymphoma, the partners are now preparing to file for a second. CD20xCD3 bispecific antibody Epkinly ...

AstraZeneca chief executive Pascal Soriot is reportedly considering moving the company's stock exchange listing from the UK to the US.